✦ LIBER ✦

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

✍ Scribed by R. N. Maini; P. C. Taylor; J. Szechinski; K. Pavelka; J. Bröll; G. Balint; P. Emery; F. Raemen; J. Petersen; J. Smolen; D. Thomson; T. Kishimoto

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 320 KB
Volume: 54
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.22033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rapid and sustained improvement in bone

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

✍ Patrick Garnero; Elizabeth Thompson; Thasia Woodworth; Josef S. Smolen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB 👁 2 views

## Abstract ## Objective To investigate the effects of tocilizumab (TCZ) added to a stable dosage of methotrexate (MTX) on biochemical markers of bone and cartilage metabolism in patients in the multicenter double‐blind, placebo‐controlled OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequa

The PREMIER study: A multicenter, random

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

✍ Ferdinand C. Breedveld; Michael H. Weisman; Arthur F. Kavanaugh; Stanley B. Cohe 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 2 views

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

Tocilizumab inhibits structural joint da

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year

✍ Joel M. Kremer; Ricardo Blanco; Marek Brzosko; Ruben Burgos-Vargas; Anne-Marie H 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB 👁 2 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ W. Rigby; H.-P. Tony; K. Oelke; B. Combe; A. Laster; C. A. von Muhlen; E. Fishel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Comparison of the clinical efficacy and

Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial

✍ J. Braun; P. Kästner; P. Flaxenberg; J. Währisch; P. Hanke; W. Demary; U. von Hi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB 👁 2 views